Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3601 AL 3615

Mitochondria- and Oxidative Stress-Targeting Substances in Cognitive Decline-Related Disorders: From Molecular Mechanisms to Clinical Evidence

Lejri I, Agapouda A, Grimm A, Eckert A.

Oxid Med Cell Longev. 2019 May 12;2019:9695412. doi: 10.1155/2019/9695412. eCollection 2019.

The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis

Cui CC, Sun Y, Wang XY, Zhang Y, Xing Y.

Medicine (Baltimore). 2019 Jul;98(27):e16091. doi: 10.1097/MD.0000000000016091.

When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram

Aga VM.

Am J Geriatr Psychiatry. 2019 Oct;27(10):1099-1107. doi: 10.1016/j.jagp.2019.04.016. Epub 2019 May 10.

Nitric oxide might be an inducing factor in cognitive impairment in Alzheimer's disease via downregulating the monocarboxylate transporter 1

Tang X, Li Z, Zhang W, Yao Z.

Nitric Oxide. 2019 Oct 1;91:35-41. doi: 10.1016/j.niox.2019.07.006. Epub 2019 Jul 18.

Optogenetic stimulation of serotonin nuclei retrieve the lost memory in Alzheimer's disease

Bostancıklıoğlu M.

J Cell Physiol. 2020 Feb;235(2):836-847. doi: 10.1002/jcp.29077. Epub 2019 Jul 22.

Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria

Triviño-Ibáñez EM, Sánchez-Vañó R, Sopena-Novales P, Romero-Fábrega JC, Rodríguez-Fernández A, Carnero Pardo C, Martínez Lozano MD, Gómez-Río M.

Medicine (Baltimore). 2019 Jul;98(29):e16509. doi: 10.1097/MD.0000000000016509.

Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients?

Panza F, Lozupone M, Bellomo A, Imbimbo BP.

Ageing Res Rev. 2019 Nov;55:100948. doi: 10.1016/j.arr.2019.100948. Epub 2019 Aug 24.

AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention

Meyer PF, McSweeney M, Gonneaud J, Villeneuve S.

Prog Mol Biol Transl Sci. 2019;165:63-106. doi: 10.1016/bs.pmbts.2019.05.001. Epub 2019 Jun 8.

Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial

Schneider LS, Geffen Y, Rabinowitz J, Thomas RG, Schmidt R, Ropele S, Weinstock M; Ladostigil Study Group.

Neurology. 2019 Oct 8;93(15):e1474-e1484. doi: 10.1212/WNL.0000000000008239. Epub 2019 Sep 6.

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

Ehrhardt S, Porsteinsson AP, Munro CA, Rosenberg PB, Pollock BG, Devanand DP, Mintzer J, Rajji TK, Ismail Z, Schneider LS, Baksh SN, Drye LT, Avramopoulos D, Shade DM, Lyketsos CG; S-CitAD Research Group.

Alzheimers Dement. 2019 Nov;15(11):1427-1436. doi: 10.1016/j.jalz.2019.06.4946. Epub 2019 Oct 3.

Antidiabetic therapies and Alzheimer disease

Bendlin BB.

Dialogues Clin Neurosci. 2019 Mar;21(1):83-91. doi: 10.31887/DCNS.2019.21.1/bblendin.

Recent advances from metabolomics and lipidomics application in alzheimer's disease inspiring drug discovery

Cuperlovic-Culf M, Badhwar A.

Expert Opin Drug Discov. 2020 Mar;15(3):319-331. doi: 10.1080/17460441.2020.1674808. Epub 2019 Oct 16.

Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease

Schelter BO, Shiells H, Baddeley TC, Rubino CM, Ganesan H, Hammel J, Vuksanovic V, Staff RT, Murray AD, Bracoud L, Riedel G, Gauthier S, Jia J, Bentham P, Kook K, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2019;72(3):931-946. doi: 10.3233/JAD-190772.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias